Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation

Cancer
Sujata PatilRobert J Motzer

Abstract

The Memorial Sloan-Kettering Cancer Center risk model classifies patients with metastatic renal cell carcinoma (RCC) by 5 pretreatment features as favorable, intermediate, and poor risk. The number of Memorial Sloan-Kettering Cancer Center patients in each risk group was examined by year of treatment to analyze stage migration. The distribution of risk groups was examined retrospectively in 789 Memorial Sloan-Kettering Cancer Center patients with metastatic RCC treated in a first-line therapy clinical trial from 1975 to 2007. Date of treatment onset was divided into 6 cohorts between 1975 and 2007 (1975-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2001, and 2001-2007). The median age of the first-line metastatic RCC clinical trial patients was 59 years (range, 20-82 years). Most patients received cytokine therapy (55%), 37% received chemotherapy/other, and 8% received vascular endothelial growth factor-targeted therapies. Overall survival increased with each consecutive cohort year group (P < .001). Median survival was 0.43 years (95% confidence interval [CI], 0.27-0.68) in the 1973-1980 cohort and 1.5 years in the 2001-2007 cohort (95% CI, 1.15-2.11). Memorial Sloan-Kettering Cancer Center risk-group distribution shifted betwee...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H IlsonG J Bosl
Nov 1, 1990·Investigational New Drugs·R MotzerG J Bosl
Apr 1, 1989·European Journal of Cancer & Clinical Oncology·C N SternbergB Boselli
Jan 1, 1985·Cancer Chemotherapy and Pharmacology·H I ScherR C Watson
Oct 1, 1985·International Journal of Radiation Oncology, Biology, Physics·T GirinskiD Chassagne
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerD M Nanus
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ P O'Brien
Jan 1, 1994·Investigational New Drugs·T M LawR J Motzer
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M MinasianS E Krown
Jan 1, 1997·Investigational New Drugs·W J BergR J Motzer
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerM Mazumdar
May 22, 2001·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·R J MotzerR M Bukowski
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Aug 31, 2002·Investigational New Drugs·Jacqueline VukyRobert J Motzer
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R J MotzerL Hooftman
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J MotzerMadhu Mazumdar
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ronald M BukowskiPaul Elson
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerJanice P Dutcher
Dec 28, 2007·Investigational New Drugs·Premal H PatelRobert J Motzer
May 27, 2008·Clinical Genitourinary Cancer·Darren R FeldmanRobert J Motzer

❮ Previous
Next ❯

Citations

Jan 28, 2012·Journal of the American Chemical Society·Gavin W CollieGary N Parkinson
Nov 26, 2011·Expert Review of Anticancer Therapy·Jean-Jacques PatardJuergen E Gschwend
Oct 2, 2015·The FEBS Journal·Erik L BrincksThomas S Griffith
Nov 17, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Robert C FlaniganCory M Hugen
Jan 24, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yunze XuYiran Huang
Feb 18, 2015·Biochemical and Biophysical Research Communications·Yuanyuan LiYing Wan
Dec 7, 2010·Cancer Treatment Reviews·G Di LorenzoG Cartenì
Dec 3, 2013·Journal of Acupuncture and Meridian Studies·Hyun-Jung HanKwang-Sup Soh
Apr 5, 2013·Therapeutic Advances in Urology·Maxine SunPierre I Karakiewicz
Jul 18, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Kelly GaudelotMichaël Perrais
May 12, 2010·Nature Reviews. Urology·Maxine SunPierre I Karakiewicz
Apr 22, 2008·The Cochrane Database of Systematic Reviews·C CoppinT Wilt
Oct 16, 2020·The Cochrane Database of Systematic Reviews·Fabian HofmannBörje Ljungberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved